Opinion|Videos|June 3, 2025
Using Ultrasensitive PSA Assays in Routine Practice
Author(s)Neal Shore, MD, FACS
Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.
Advertisement
Episodes in this series
Practical Considerations for Ultrasensitive PSA Testing
Key Themes:
- Feasibility of implementing ultrasensitive PSA assays in community practice
- Logistical challenges including cost and standardization
- Clinical interpretation considerations
Expert Insights:
- Dr Shore addressed the practicality of using ultrasensitive PSA assays in routine clinical practice.
The discussion covered pros and cons, cost implications, assay standardization challenges, and the nuances of clinical interpretation.
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5